NASDAQ$GH
Guardant Health Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported revenue of $92.1 million, driven by a 52% year-over-year growth in clinical volume.
Guardant Health reported a revenue of $92.1 million for the second quarter of 2021, a 39% increase compared to the same period in 2020. The company saw growth in clinical and biopharmaceutical tests, and expanded its product portfolio.
- Revenue of $92.1 million for the second quarter of 2021, an increase of 39% over the corresponding period of 2020
- Reported 20,830 tests to clinical customers and 3,653 tests to biopharmaceutical customers in the second quarter of 2021, representing an increase of 52% and 30%, respectively, over the second quarter of 2020
- Enrolled 10,000th patient in ECLIPSE trial and plans to launch a blood-based screening LDT in the first half of 2022
- Expanded Guardant360 portfolio with launch of TissueNext™ and Response™ tests
Headline financials
Revenue & EPS history
Guardant Health · Revenue · Quarterly
$92.1M
Revenue by segment
Guardant Health · $72.6M total across 1 segment · Q2 2021
- Oncology Revenue$72.6M+42.4%100.0%
Forward guidance
Due to continued uncertainty around the global COVID pandemic, Guardant Health is maintaining its previous 2021 revenue guidance. The Company continues to expect full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Clinical volumes for 2021 are expected to be greater than 90,000 tests, growing at least 42% over 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+3.8%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+3.9%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+41.3%
Q4 2018
Best reaction
-30.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | +6.6% | +36.1% | |
| Q4 2025 | -3.0% | -10.4% | -19.9% | |
| Q3 2025 | +28.5% | +35.8% | +50.0% | |
| Q1 2025 | +3.5% | -11.2% | -14.0% | |
| Q4 2024 | -9.6% | -8.9% | -2.7% | |
| Q3 2024 | +21.6% | +24.8% | +56.8% | |
| Q2 2024 | -5.9% | -5.3% | -26.2% | |
| Q1 2024 | +20.0% | +32.7% | +53.8% | |
| Q4 2023 | -14.3% | -13.8% | -23.9% | |
| Q3 2023 | -8.5% | -24.7% | -10.2% | |
| Q2 2023 | +4.6% | +1.9% | -3.1% | |
| Q1 2023 | +17.2% | +12.1% | +38.5% | |
| Q4 2022 | +4.4% | +11.7% | -12.6% | |
| Q3 2022 | +3.3% | -3.1% | +17.5% | |
| Q2 2022 | +1.6% | -6.0% | +2.0% | |
| Q1 2022 | -30.0% | -44.3% | -32.3% | |
| Q4 2021 | +6.0% | +7.0% | -4.3% | |
| Q3 2021 | -3.8% | -5.8% | -20.8% | |
| Q2 2021 | +0.2% | -7.7% | +15.7% | |
| Q1 2021 | -3.1% | -14.0% | -15.8% | |
| Q4 2020 | -6.7% | -5.0% | -15.3% | |
| Q3 2020 | -0.4% | -1.1% | +9.0% | |
| Q2 2020 | +0.6% | -4.0% | +6.8% | |
| Q1 2020 | +9.0% | +19.6% | +2.9% | |
| Q4 2019 | -14.7% | -2.1% | -25.9% | |
| Q3 2019 | +11.2% | +13.8% | +14.4% | |
| Q2 2019 | +25.8% | +18.2% | -5.2% | |
| Q1 2019 | +17.4% | +12.0% | +40.3% | |
| Q4 2018 | +41.3% | +46.6% | +7.9% | |
| Q3 2018 | -6.7% | +3.1% | -2.7% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro